Patent Portfolio Management

Filling the gaps in your patent strategy

Tuesday, February 27, 2007

About

Make the most of your company's key assets

A successful patent portfolio is your company's most valuable asset. As the invisible infrastructure that controls the worth of the company's products, you need to control and maximize your current patent portfolio, and plan for growth.

Ensure corporate longevity by turning paper into profit

In an era of rapid scientific and legal change, you need to revise your patent portfolio management strategy in light of concerns raised by

  • trends in Orange Book listing practices,
  • emerging global market considerations, and
  • the ever-evolving state of patent reform

In the publication from the American Conference Institute's Pharma/Biotech Industry Forum on Patent Portfolio Management, learn how to eliminate the variable of uncertainty by structuring a patent portfolio management strategy that will grow profit, stock value and generate new business.

Contents & Contributors

About

Make the most of your company's key assets

A successful patent portfolio is your company's most valuable asset. As the invisible infrastructure that controls the worth of the company's products, you need to control and maximize your current patent portfolio, and plan for growth.

Ensure corporate longevity by turning paper into profit

In an era of rapid scientific and legal change, you need to revise your patent portfolio management strategy in light of concerns raised by

  • trends in Orange Book listing practices,
  • emerging global market considerations, and
  • the ever-evolving state of patent reform

In the publication from the American Conference Institute's Pharma/Biotech Industry Forum on Patent Portfolio Management, learn how to eliminate the variable of uncertainty by structuring a patent portfolio management strategy that will grow profit, stock value and generate new business.

Contents & Contributors


MAKING THE CRITICAL DETERMINATION OF WHEN R&D BECOMES IP
Peggy Albanese, Enzo Pharmaceuticals, Inc. (Bridgewater, NJ)
Irving Newman, The Sanofi-Aventis Group (Bridgewater, NJ)
Michael N. Mercanti, Lucas and Mercanti, LLP (New York, NY)

PROTECTING MARKET SHARE THROUGH COMPETITIVE INTELLIGENCE IN THE PHARMACEUTICAL INDUSTRY
Pamela C. Ancona, Crowell Moring (New York, NY)

PROTECTING MARKET SHARE THROUGH COMPETITIVE INTELLIGENCE
John C. Todaro, Merck & Co., Inc. (Rahway, NJ)

DRUG LABELING IN A POST-ORANGE BOOK WORLD
Terry G. Mahn, Fish & Richardson, P.C. (Washington, DC)

PATENT PORTFOLIO STRATEGIES AND LIFE CYCLE MANAGEMENT: RECENT INEQUITABLE CONDUCT DECISIONS
Sandra A. Bresnick, Sidley Austin LLP (New York, NY)

THE FUTURE OF "FOLLOW-ON" BIOLOGICS: TRICKLE OR ONSLAUGHT? - THE BRANDED PERSPECTIVE
Arie M. Michelsohn, PhD, Finnegan, Henderson, Farabow, Garrett & Dunbar LLP (Washington, DC)

UNDERSTANDING THE PROPOSED NEW USPTO RULES
Michele A. Cimbala, PhD, Sterne, Kessler, Goldstein & Fox P.L.L.C.(Washington, DC) BRACING FOR THE IMPACT OF PATENT REFORM ON PATENT PORTFOLIO MANAGEMENT: PROSPECTS FOR LEGISLATION IN THE 110TH CONGRESS
Bruce Lehman, International Intellectual Property Institute (IIPI);Akin, Gump, Strauss, Hauer & Feld (Washington, DC)

EXAMINING SPECIAL PORTFOLIO CONSIDERATIONS THE ARISE WITH IP OWNERSHIP IN COLLABORATION
Thomas J. Kowalski, Frommer Lawrence & Haug LLP (New York, NY)
Dr. Judy Jarecki-Black, Merial Limited (Duluth, GA)

IN-LICENSING TECHNOLOGY: LESSONS LEARNED
Richard J. Berman, Arent Fox (Washington, DC)

CONTROLLING SPIRALING COSTS AS PIPELINES GET FILLED AND PORTFOLIOS GO GLOBAL Tedd Van Buskirk, Hogan and Hartson LLP (New York, NY)
Debra Condino, Allergan, Inc. (Irvine, CA)

ADVANCED STRATEGIC BUSINESS CONSIDERATIONS FOR MANEUVERING IN THE GLOBAL PATENT MARKET
Jane T. Gunnison, Fish & Neave IP Group, Ropes & Gray (New York, NY)
Romy L. Celli, Sughrue Mion, PLLC (Mountain View, CA)



DOCUMENT TYPES: PRESENTATIONS AVAILABLE: 0